Beyond analysts' top-and-bottom-line estimates for Abbott (ABT), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended September 2026.
Most income investors chase flashy yields and overlook the quiet compounders that have raised their dividends through recessions, rate shocks, and global pandemics.
ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.
| Pharmaceuticals Industry | Healthcare Sector | Robert Ford CEO | XSTU Exchange | 002824100 CUSIP |
| US Country | 115,000 Employees | 15 Oct 2026 Last Dividend | 2 Jan 2013 Last Split | 13 Jan 1978 IPO Date |
Abbott Laboratories is a global healthcare company that engages in the discovery, development, manufacturing, and sale of a wide range of health care products. With its foundation laid in 1888, and headquartered in North Chicago, Illinois, the company has established a significant presence worldwide. Abbott operates across four main sectors: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, catering to a diverse range of healthcare needs from generic pharmaceuticals to advanced medical devices.
Abbott Laboratories offers a comprehensive portfolio of products and services across various healthcare domains: